Giotrif Label to Add Acute Pancreatitis as Clinically Significant ADR

The Ministry of Health, Labor and Welfare (MHLW) issued a notification on April 21, ordering a label revision for Nippon Boehringer Ingelheim’s cancer drug Giotrif (afatinib) to add acute pancreatitis as a clinically significant adverse drug reaction (ADR). The Giotrif...read more